Literature DB >> 10639052

The cause of neuronal degeneration in Alzheimer's disease.

J C Vickers1, T C Dickson, P A Adlard, H L Saunders, C E King, G McCormack.   

Abstract

Alzheimer's disease is associated with a specific pattern of pathological changes in the brain that result in neurodegeneration and the progressive development of dementia. Pathological hallmarks common to the disease include beta-amyloid plaques, dystrophic neurites associated with plaques and neurofibrillary tangles within nerve cell bodies. The exact relationship between these pathological features has been elusive, although it is clear that beta-amyloid plaques precede neurofibrillary tangles in neocortical areas. Examination of the brains of individuals in the preclinical stage of the disease have shown that the earliest form of neuronal pathology associated with beta-amyloid plaques resembles the cellular changes that follow structural injury to axons. Thus, the development of beta-amyloid plaques in the brain may cause physical damage to axons, and the abnormally prolonged stimulation of the neuronal response to this kind of injury ultimately results in the profound cytoskeletal alterations that underlie neurofibrillary pathology and neurodegeneration. Therapeutically, inhibition of the neuronal reaction to physical trauma may be a useful neuroprotective strategy in the earliest stages of Alzheimer's disease.

Entities:  

Mesh:

Year:  2000        PMID: 10639052     DOI: 10.1016/s0301-0082(99)00023-4

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  39 in total

Review 1.  Alzheimer's disease: amyloid beta-peptide antibody vaccine as plaque remover.

Authors:  A Kumar
Journal:  J Biosci       Date:  2000-12       Impact factor: 1.826

Review 2.  Protein aggregates and dementia: is there a common toxicity?

Authors:  S Lovestone; D M McLoughlin
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-02       Impact factor: 10.154

Review 3.  In vivo amyloid imaging in Alzheimer's disease.

Authors:  H I Sair; P M Doraiswamy; J R Petrella
Journal:  Neuroradiology       Date:  2004-01-23       Impact factor: 2.804

4.  N-PEP-12--a novel peptide compound that protects cortical neurons in culture against different age and disease associated lesions.

Authors:  M Windisch; B Hutter-Paier; E Grygar; E Doppler; H Moessler
Journal:  J Neural Transm (Vienna)       Date:  2005-03-07       Impact factor: 3.575

Review 5.  Animal models in the drug discovery pipeline for Alzheimer's disease.

Authors:  Debby Van Dam; Peter Paul De Deyn
Journal:  Br J Pharmacol       Date:  2011-10       Impact factor: 8.739

6.  Mitofusin2 mutations disrupt axonal mitochondrial positioning and promote axon degeneration.

Authors:  Albert L Misko; Yo Sasaki; Elizabeth Tuck; Jeffrey Milbrandt; Robert H Baloh
Journal:  J Neurosci       Date:  2012-03-21       Impact factor: 6.167

Review 7.  Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease.

Authors:  Imrich Blasko; Beatrix Grubeck-Loebenstein
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

8.  The role of adenosine in Alzheimer's disease.

Authors:  Anisur Rahman
Journal:  Curr Neuropharmacol       Date:  2009-09       Impact factor: 7.363

9.  Capzb2 interacts with beta-tubulin to regulate growth cone morphology and neurite outgrowth.

Authors:  David A Davis; Meredith H Wilson; Jodel Giraud; Zhigang Xie; Huang-Chun Tseng; Cheryl England; Haya Herscovitz; Li-Huei Tsai; Ivana Delalle
Journal:  PLoS Biol       Date:  2009-10-06       Impact factor: 8.029

10.  Investigation of the association between interleukin-1beta polymorphism and normal tension glaucoma.

Authors:  Chun Yuan Wang; Ying-Cheng Shen; Chien-Hui Su; Fai-Yun Lo; Shi-Huang Lee; Hin-Yeung Tsai; Seng-Sheen Fan
Journal:  Mol Vis       Date:  2007-05-14       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.